BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pallet N, Karras A, Thervet E, Gouya L, Karim Z, Puy H. Porphyria and kidney diseases. Clin Kidney J 2018;11:191-7. [PMID: 29644058 DOI: 10.1093/ckj/sfx146] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology 2023:S0016-5085(22)01356-7. [PMID: 36642627 DOI: 10.1053/j.gastro.2022.11.034] [Reference Citation Analysis]
2 Traber GM, Yu AM. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. J Pharmacol Exp Ther 2023;384:133-54. [PMID: 35680378 DOI: 10.1124/jpet.122.001234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
3 Goldman S, Zidan O, Edel Y, Schechter A, Mimouni T, Hodak E, Cohen S, Mamet R, Rozen-Zvi B, Levi A. Plasma porphyrins among end stage renal disease patients and cutaneous symptoms- is there still an association? Mol Genet Metab Rep 2022;33:100928. [PMID: 36281443 DOI: 10.1016/j.ymgmr.2022.100928] [Reference Citation Analysis]
4 Wang B, Ventura P, Takase KI, Thapar M, Cassiman D, Kubisch I, Liu S, Sweetser MT, Balwani M. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study. Orphanet J Rare Dis 2022;17:327. [PMID: 36028858 DOI: 10.1186/s13023-022-02463-x] [Reference Citation Analysis]
5 Storjord E, Airila-Månsson S, Karlsen K, Madsen M, Dahl JA, Landsem A, Fure H, Ludviksen JK, Fjøse JØ, Dickey AK, Karlsen BO, Waage Nielsen E, Mollnes TE, Brekke OL. Dental and Periodontal Health in Acute Intermittent Porphyria. Life (Basel) 2022;12:1270. [PMID: 36013449 DOI: 10.3390/life12081270] [Reference Citation Analysis]
6 Ricci A, Sandri G, Marcacci M, Di Pierro E, Granata F, Cuoghi C, Marchini S, Pietrangelo A, Ventura P. Endothelial Dysfunction in Acute Hepatic Porphyrias. Diagnostics 2022;12:1303. [DOI: 10.3390/diagnostics12061303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ventura P, Ricci A. Givosiran for the treatment of acute hepatic porphyria. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2075848] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Marcacci M, Ricci A, Cuoghi C, Marchini S, Pietrangelo A, Ventura P. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives. Orphanet J Rare Dis 2022;17:160. [PMID: 35392955 DOI: 10.1186/s13023-022-02314-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Sardh E, Harper P. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. J Intern Med. [DOI: 10.1111/joim.13443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sirch C, Khanna N, Frassetto L, Bianco F, Artero ML. Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report. World J Transplant 2022; 12(1): 8-14 [DOI: 10.5500/wjt.v12.i1.8] [Reference Citation Analysis]
11 Poli A, Schmitt C, Moulouel B, Mirmiran A, Talbi N, Rivière S, Cerutti D, Bouchoule I, Faivre A, Grobost V, Douillard C, Duchêne F, Fiorentino V, Dupré T, Manceau H, Peoc'h K, Puy H, Lefebvre T, Gouya L. Givosiran in acute intermittent porphyria: A personalized medicine approach. Molecular Genetics and Metabolism 2022. [DOI: 10.1016/j.ymgme.2022.01.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
12 Ricci A, Guida CC, Manzini P, Cuoghi C, Ventura P. Kidney Involvement in Acute Hepatic Porphyrias: Pathophysiology and Diagnostic Implications. Diagnostics (Basel) 2021;11:2324. [PMID: 34943561 DOI: 10.3390/diagnostics11122324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Anderson KE, Desnick RJ, Stewart MF, Ventura P, Bonkovsky HL. Acute Hepatic Porphyrias: "Purple Flags"-Clinical Features that should Prompt Specific Diagnostic Testing. Am J Med Sci 2021:S0002-9629(21)00337-2. [PMID: 34606756 DOI: 10.1016/j.amjms.2021.09.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Østergaard MGØ, Erlandsen EJ, Thomsen HH, Randers E. Peritoneal dialysis resulting in discontinuance of recurring attacks of acute intermittent porphyria: A case report. Semin Dial 2021. [PMID: 34558740 DOI: 10.1111/sdi.13025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Gilles A, Vermeersch S, Vermeersch P, Wolff F, Cotton F, Tilleux S, Cassiman D. Expert consensus statement on acute hepatic porphyria in Belgium. Acta Clin Belg 2021;:1-7. [PMID: 34369323 DOI: 10.1080/17843286.2021.1961056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Linenberger M, Fertrin KY. Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP. Hematology Am Soc Hematol Educ Program 2020;2020:400-10. [PMID: 33275677 DOI: 10.1182/hematology.2020000124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
17 To-Figueras J, Wijngaard R, García-Villoria J, Aarsand AK, Aguilera P, Deulofeu R, Brunet M, Gómez-Gómez À, Pozo OJ, Sandberg S. Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran. J Inherit Metab Dis 2021;44:961-71. [PMID: 33861472 DOI: 10.1002/jimd.12391] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
18 Lissing M, Nowak G, Adam R, Karam V, Boyd A, Gouya L, Meersseman W, Melum E, Ołdakowska-Jedynak U, Reiter FP, Colmenero J, Sanchez R, Herden U, Langendonk J, Ventura P, Isoniemi H, Boillot O, Braun F, Perrodin S, Mowlem E, Wahlin S; European Liver and Intestine Transplant Association. Liver Transplantation for Acute Intermittent Porphyria. Liver Transpl 2021;27:491-501. [PMID: 33259654 DOI: 10.1002/lt.25959] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
19 Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB. The growth of siRNA-based therapeutics: Updated clinical studies. Biochem Pharmacol 2021;189:114432. [PMID: 33513339 DOI: 10.1016/j.bcp.2021.114432] [Cited by in Crossref: 90] [Cited by in F6Publishing: 105] [Article Influence: 45.0] [Reference Citation Analysis]
20 Ortiz A. Ckj consolidation among Q1 Urology and Nephrology journals. Clin Kidney J 2020;13:723-7. [PMID: 33123351 DOI: 10.1093/ckj/sfaa197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Kim EH, Park S, Kim YK, Moon M, Park J, Lee KJ, Lee S, Kim YP. Self-luminescent photodynamic therapy using breast cancer targeted proteins. Sci Adv 2020;6:eaba3009. [PMID: 32917700 DOI: 10.1126/sciadv.aba3009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
22 Halloy F, Iyer PS, Ćwiek P, Ghidini A, Barman-Aksözen J, Wildner-Verhey van Wijk N, Theocharides APA, Minder EI, Schneider-Yin X, Schümperli D, Hall J. Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of erythropoietic protoporphyria. Nucleic Acids Res 2020;48:4658-71. [PMID: 32313951 DOI: 10.1093/nar/gkaa229] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
23 Gouya L, Ventura P, Balwani M, Bissell DM, Rees DC, Stölzel U, Phillips JD, Kauppinen R, Langendonk JG, Desnick RJ, Deybach JC, Bonkovsky HL, Parker C, Naik H, Badminton M, Stein PE, Minder E, Windyga J, Bruha R, Cappellini MD, Sardh E, Harper P, Sandberg S, Aarsand AK, Andersen J, Alegre F, Ivanova A, Talbi N, Chan A, Querbes W, Ko J, Penz C, Liu S, Lin T, Simon A, Anderson KE. EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology 2020;71:1546-58. [PMID: 31512765 DOI: 10.1002/hep.30936] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 20.7] [Reference Citation Analysis]
24 Harte J, Chapagain A, Sarkany RP, Chaudhri S. The Case | Bullous eruptions in end-stage renal failure. Kidney International 2020;97:1067-1068. [DOI: 10.1016/j.kint.2019.11.038] [Reference Citation Analysis]
25 Bustos J, Vargas L, Quintero R. Acute intermittent porphyria: A case report. Biomedica 2020;40:14-9. [PMID: 32220159 DOI: 10.7705/biomedica.4767] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
26 Halloy F, Iyer PS, Ćwiek P, Ghidini A, Barman-aksözen J, van Wijk NW, Theocharides A, Minder EI, Schneider-yin X, Schümperli D, Hall J. Delivery of oligonucleotides to bone marrow to modulate ferrochelatase splicing in a mouse model of Erythropoietic Protoporphyria.. [DOI: 10.1101/2020.02.14.949297] [Reference Citation Analysis]
27 Bronisch O, Stauch T, Haverkamp T, Beykirch MK, Petrides PE. Acute porphyrias: a German monocentric study of the biochemical, molecular genetic, and clinical data of 62 families. Ann Hematol 2019;98:2683-91. [DOI: 10.1007/s00277-019-03831-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
28 Jaramillo-Calle DA, Solano JM, Rabinstein AA, Bonkovsky HL. Porphyria-induced posterior reversible encephalopathy syndrome and central nervous system dysfunction. Mol Genet Metab 2019;128:242-53. [PMID: 31706631 DOI: 10.1016/j.ymgme.2019.10.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
29 Hermann M, Bilandzic L, Stölzel U, Hinkel UP. 29-jährige Patientin mit Syndrom der inadäquaten ADH-Sekretion unklarer Ursache. Nephrologe 2019;14:287-290. [DOI: 10.1007/s11560-019-0345-8] [Reference Citation Analysis]
30 Poh-fitzpatrick MB. Photocutaneous Porphyrias. Curr Derm Rep 2019;8:52-62. [DOI: 10.1007/s13671-019-0253-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Granata F, Mendez M, Brancaleoni V, Castelbon FJ, Graziadei G, Ventura P, Di Pierro E. Molecular characterization, by digital PCR analysis of four HMBS gene mutations affecting the ubiquitous isoform of Porphobilinogen Deaminase (PBGD) in patients with Acute Intermittent Porphyria (AIP). Mol Genet Metab 2018;125:295-301. [PMID: 30201327 DOI: 10.1016/j.ymgme.2018.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]